On March 1, 2022, Vivos Therapeutics, Inc. (the “Company”), with the unanimous approval of the Board of Directors of the Company, provided Dr. G. Dave Singh, the Company's Chief Medical Officer (“Dr. Singh”), with notice of termination of his employment with the Company “for cause” pursuant to the terms Dr. Singh's employment agreement with the Company, dated October 9, 2020. As such, Dr. Singh is no longer affiliated with the Company effective March 1, 2022.